SCROLL
SCROLL
Our promise
We believe in the power of our path — as meaningful as its manifestation.
We want to make visible what lies underneath our efforts, to demonstrate how the progress of oncology care starts from here.
We exist to push humanity forward.
Oncology forward.
Whatever it takes.
People
A community of ambitious people of science.
“Our most precious resources are the scientists. We want to get on the top of the game again – also for them.”
History
A glorious past, embraced with resilience.
“When I remember Nerviano’s golden age with the people that worked there, I always hear them say when we were warriors.”
Location
A place, around which
everyone is tied to.
“Companies come and go, but scientists have been doing research here since ’60s.”
About us
Research and development of personalized therapies for cancer patients
We have a mission. To improve patients’ health through our unwavering commitment to discover, develop and deliver life-changing molecules.
Every day we discover, develop, and create new molecules and new personalized oncology therapeutic strategies to improve the lives of people suffering from cancer.
NMS Group is the largest company in Italy committed to oncology innovation and the only institution able to manage the entire integrated R&D chain: from the first steps of the pre-clinical phase to the packaging of the finished product, thanks to the Group’s subsidiaries that each excels in its field.
Perseverance, Respect, Integrity, Dedication and Empathy, we PRIDE our values.
The international certifications, the continuous interactions with public and private scientific institutions and the strong network of collaborations with the scientific community and other industries are the guarantee of our excellence.
NMS Group
This allows us to guarantee the best at every step of the process: from the research of new molecular targets to preclinical trails, clinical trials, commercial manufactory to packaging of innovative drugs, up to regulatory approvals in various countries and patents granted all over the globe.
DISCOVER MORE
The Group’s subsidiaries are: Nerviano Medical Sciences, Accelera and NerPharMa.
Nerviano Medical
Sciences
Nerviano MS represents the innovative core of our Group and is engaged in the discovery and development of new oncology drugs. Each day, our 130 researchers seek and develop new targeted therapy opportunities to generate highly effective and selective molecules.
DISCOVER MORE
Accelera
Accelera is one of the few Italian companies committed to preclinical research and experimentation. It offers integrated high level services for biotech and pharmaceutical companies, as well as academic Institutes and non-profit organizations at a global level.
DISCOVER MORE
NerPharMa
Nerpharma deals with the development and manufacturing of products, beginning with the formulation of the active ingredient up to packaging, from the management of the clinical distribution chain to the regulatory approvals in the different countries.
DISCOVER MORE
Latest News & Events
CPhI Worldwide
Where: Fiera Milano, Milan, Italy
When: 9 November – 11 November 2021
CPhI Worldwide 2021 has established itself as the flagship event for the pharmaceutical industry. The upcoming edition will be staged from 9th to 11th November at Fiera Milano.
NMS Group is participating for the first time as an integrated, fully fledged R&D organization. We will be exhibiting in the featured area of ICSE where outsourcing providers, from contract manufacturing, research to services are all gathered in one place.
Pharma Tech Outlook Names NMS Group a Top Drug Discovery and Development Solution Provider in Europe 2021
Nerviano, 29 September 2021
NMS Group is proud to be named by Pharma Tech Outlook as Top drug discovery and development solution providers in Europe for 2021 and featured in the cover of this special issue. The annual list showcases companies that are providing cutting-edge drug discovery and development tech solutions and services. Determined by a panel of experts and members of Pharma Tech Outlook’s editorial board, NMS Group has come on top in terms of its ability to innovate in drug R&D process, and to meet client requirements, through support and customization.
(Click the title for the complete article)
Entrectinib, the kinase inhibitor drug initially discovered and developed by Nerviano Medical Sciences approved by AIFA in two oncology indications
Nerviano, 14 September 2021
Entrectinib, the kinase inhibitor drug that was initially discovered and developed by Nerviano Medical Sciences (a member of NMS Group) and that is now marketed by Roche and partners, has received approval for marketing and reimbursement from the Italian drug agency AIFA in two oncology indications: lung cancer ROS1 kinase fusion positive, and any solid tumor type with NTRK kinase gene fusions.
(Click the title for the complete article)
Latest Events
Latest News
Welcome and Check out our new motion picture!